Finnish nanonization specialist Nanoform has announced the appointments of Eric Peter and Sergie Letser to the company’s US business development team. In January 2020, Nanoform announced the appointment of Sally Langa as its new Head of US Sales, and in February, the company announced that it had established a US subsidiary. Langa has since left the company.
Peter was most recently in a US Business Development for Hovione and previously held business development roles at Patheon, Cetero Research, and Aptuit. Letser was most recently Director of Business Development at Porton Pharma Solutions; his previous experience included BD roles at Johnson Matthey Pharma Services and Cambridge Major Laboratories.
Nanoform Chief Commercial Officer Christian Jones commented, “It gives me great pleasure to welcome Eric and Sergie to Nanoform. Their combined commercial development expertise will be invaluable as we continue to increase the traction of our proprietary nanoparticle engineering technology in the US and enable more patients around the world to benefit from enhanced medicines.”
Peter said, “I am thrilled to be joining such a vibrant team that is dedicated to revolutionising pharmaceutical development. I look forward to introducing Nanoform’s award-winning technology to partners in the US and working with them to solve their complex formulation challenges.”
Letser said, “Nanoform has developed an outstanding technology that will enable pharmaceutical and biotechnology companies to significantly increase the solubility and bioavailability of their drugs. I anticipate exciting times ahead, working with the rest of the commercial development team to bring next-generation pharmaceutical products to the market.”
Read the Nanoform press release.
